- MyndTec Inc. (MYTC) has added its newest product, MyndStep, to its functional electric stimulation portfolio
- The MyndStep device addresses foot drop ailments and is small and light, worn in a cuff just below the knee
- The company has entered into a supply and distribution agreement with Guangzhou Longest Science & Technology Co. Ltd. (GLST) for the exclusive distribution of the device, available in the United States and Canada by Q4 2022
- MyndTec (MYTC) is trading steady at C$0.90 per share
MyndTec (MYTC) has added its newest product, MyndStep, to its functional electric stimulation (FES) portfolio.
The MyndStep device addresses foot drop ailments and is small and light, worn in a cuff just below the knee, it is connected to a user App, available for download on IoS and Android, and is Bluetooth enabled.
The company has entered into a supply and distribution agreement with Guangzhou Longest Science & Technology Co. Ltd. (GLST) for the exclusive distribution of the MyndStep Foot Drop device, available in the United States and Canada by Q4 2022.
MyndTec’s CEO, Craig Leon, explained that MyndStep is a natural complement to the company’s flagship upper body FES product, MyndMove.
“The addition of our newest FES lower body product MyndStep, reinforces our commitment to providing clinics, rehabilitation centers and physicians with innovative products focused on improving patient care and quality of life. We look forward to introducing our latest product to our existing and new customers, and more importantly, introducing patients to an innovative technology which will help them regain function and mobility and restore independence, one step at a time.”
MyndTec Inc. (MYTC) is a medical technology company. It researches, develops, and distributes innovative therapies designed to improve function, maximize independence, and enhance the quality of life for individuals with upper limb paralysis due to stroke, spinal cord injury or traumatic brain injury. The firm develops non-invasive neurological and nervous system electrical stimulation therapeutics for treating neurological diseases, specifically targeted to markets with large, growing, and global patient populations.
MyndTec (MYTC) is trading steady at C$0.90 per share.